Two medicines, side by side
Cefdinir vs cefpodoxime
Cefdinir and cefpodoxime are both labeled for bacterial infections. Drugs@FDA records approvals of cefdinir since 1997 and of cefpodoxime since 1992. Pharmacies paid $0.458 per cefdinir 300 mg capsule and $1.04 per cefpodoxime 100 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like.
Check it at the source: the cefdinir FDA label on DailyMed (effective October 14, 2025); the cefpodoxime FDA label on DailyMed (effective July 30, 2026).
Highlights of the cefdinir record
Cefdinir (Omnicef) · label of October 14, 2025
Used for
From the label: indicationsTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. […]
On the market
- Earliest approval on file
- December 4, 1997
- Generic labelers
- 26 labelers
- Pharmacy cost
- $0.458 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 11
Highlights of the cefpodoxime record
Cefpodoxime (Vantin) · label of July 30, 2026
Used for
From the label: indicationsCefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. […]
On the market
- Earliest approval on file
- August 7, 1992
- Generic labelers
- 11 labelers
- Pharmacy cost
- $1.04 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Source: FDA drug labels via openFDA (Cefdinir label of October 14, 2025, Cefpodoxime label of July 30, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do cefdinir and cefpodoxime differ on the record?
Both are in FDA's class cephalosporin antibacterials.
Generics: cefdinir since 2006; cefpodoxime since 2002 (Drugs@FDA).
| Cefdinir | Cefpodoxime | |
|---|---|---|
| Labeled for | Bacterial infections | Bacterial infections |
| Pharmacologic class | Cephalosporin Antibacterial | Cephalosporin Antibacterial |
| How it works (label) | n/a | Mechanism of Action Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. |
| Half-life (label) | n/a | In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours. |
| Earliest approval on file (Drugs@FDA) | December 4, 1997 | August 7, 1992 |
| First generic approved | May 19, 2006 | May 31, 2002 |
| Generic labelers (NDC) | 26 labelers | 11 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.458 per capsule (Cefdinir 300 mg capsule) | $1.04 per tablet (Cefpodoxime 100 mg tablet) |
| 12-month price change | +0.7% | -14% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 11 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 7,628 | 976 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to cefdinir
- every medicine labeled for the same conditions